Cue Biopharma Files Proxy Materials
Ticker: CUE · Form: DEFA14A · Filed: May 24, 2024 · CIK: 1645460
Sentiment: neutral
Topics: proxy, shareholder-meeting, corporate-governance
TL;DR
Cue Biopharma just dropped proxy docs. Big shareholder vote coming soon.
AI Summary
Cue Biopharma, Inc. filed a Definitive Additional Materials (DEFA14A) on May 24, 2024. This filing is related to proxy materials, indicating a shareholder meeting or vote is approaching. The company, formerly known as Imagen Biopharma, Inc., is based in Boston, MA.
Why It Matters
This filing signals upcoming shareholder decisions or meetings, which could impact corporate governance and future strategic directions for Cue Biopharma.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- Imagen Biopharma, Inc. (company) — Former company name
- 0000950170-24-064528 (filing_id) — Accession Number
- 20240524 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
Who is the filing company?
The filing company is Cue Biopharma, Inc.
When was this filing made?
The filing was made on May 24, 2024.
What was Cue Biopharma's former name?
Cue Biopharma, Inc. was formerly known as Imagen Biopharma, Inc.
Where is Cue Biopharma, Inc. located?
Cue Biopharma, Inc. is located at 40 Guest Street, Boston, MA 02135.
Filing Stats: 247 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-05-24 16:00:08
Filing Documents
- proxy_card-defa14a.htm (DEFA14A) — 27KB
- img58106006_0.jpg (GRAPHIC) — 105KB
- img58106006_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-064528.txt ( ) — 256KB
From the Filing
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Cue Biopharma, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Explanatory Note Cue Biopharma, Inc. (the “Company”) is filing the attached proxy card as an amendment to the Definitive Proxy Statement on Schedule 14A that was filed by the Company with the U.S. Securities and Exchange Commission on April 26, 2024 (the “Proxy Statement”). After filing the Proxy Statement, the Company discovered that the form of proxy card was inadvertently omitted from the Proxy Statement. The proxy card has been made available to the Company’s stockholders in the form attached hereto. Please note that no changes have been made to the body of the Proxy Statement. This Form DEFA14A is being filed solely to correct the EDGAR version of the Proxy Statement to include the form of proxy card to stockholders.